CONTEXT: There is agreement that warfarin decreases stroke risk in patients with atrial fibrillation (AF), but prior studies suggest that warfarin is markedly underused, for unclear reasons. OBJECTIVE: To determine if warfarin is underused in the treatment of patients with atrial fibrillation. DESIGN: Cross-sectional. SETTING: Tertiary care VA hospital. PATIENTS: All patients with a hospital or outpatient diagnosis of AF between 10/1/95 and 5/31/98. DATA COLLECTION: One or more physician investigators reviewed pertinent records for each patient. When any of the 3 investigators thought warfarin might be indicated, the patient's primary care provider completed a survey regarding why warfarin was not used. RESULTS: Of 1,289 AF patients, 844 (65%) had filled at least 1 warfarin prescription. Of the 445 remaining, 19 had died, 5 had inadequate medical records, and 54 received warfarin elsewhere, leaving 367 patients. Of these, 160 had no documented AF, 53 had only a history of AF, and 49 had only transient AF. Of the remaining 105 patients, 17 refused warfarin therapy and 72 had documented contraindications to warfarin use including bleeding risk or history, fall risk, alcohol abuse, or other compliance problems. The reasons for not using warfarin among the 16 patients remaining included provider oversight (n = 4) and various reasons suggesting provider knowledge deficits. CONCLUSION: In contrast to prior studies that suggested that warfarin is markedly underused, we found that few patients with AF and no contraindication to anticoagulation were not receiving warfarin. We believe that differing study methodologies, including the use of physician review and provider survey, may explain our markedly different rate of warfarin underutilization, although local institutional factors cannot be excluded. The findings suggest that primary providers may be far more compliant with the standard of care for patients with atrial fibrillation than previously believed.
CONTEXT: There is agreement that warfarindecreases stroke risk in patients with atrial fibrillation (AF), but prior studies suggest that warfarin is markedly underused, for unclear reasons. OBJECTIVE: To determine if warfarin is underused in the treatment of patients with atrial fibrillation. DESIGN: Cross-sectional. SETTING: Tertiary care VA hospital. PATIENTS: All patients with a hospital or outpatient diagnosis of AF between 10/1/95 and 5/31/98. DATA COLLECTION: One or more physician investigators reviewed pertinent records for each patient. When any of the 3 investigators thought warfarin might be indicated, the patient's primary care provider completed a survey regarding why warfarin was not used. RESULTS: Of 1,289 AFpatients, 844 (65%) had filled at least 1 warfarin prescription. Of the 445 remaining, 19 had died, 5 had inadequate medical records, and 54 received warfarin elsewhere, leaving 367 patients. Of these, 160 had no documented AF, 53 had only a history of AF, and 49 had only transient AF. Of the remaining 105 patients, 17 refused warfarin therapy and 72 had documented contraindications to warfarin use including bleeding risk or history, fall risk, alcohol abuse, or other compliance problems. The reasons for not using warfarin among the 16 patients remaining included provider oversight (n = 4) and various reasons suggesting provider knowledge deficits. CONCLUSION: In contrast to prior studies that suggested that warfarin is markedly underused, we found that few patients with AF and no contraindication to anticoagulation were not receiving warfarin. We believe that differing study methodologies, including the use of physician review and provider survey, may explain our markedly different rate of warfarin underutilization, although local institutional factors cannot be excluded. The findings suggest that primary providers may be far more compliant with the standard of care for patients with atrial fibrillation than previously believed.
Authors: S F Jencks; T Cuerdon; D R Burwen; B Fleming; P M Houck; A E Kussmaul; D S Nilasena; D L Ordin; D R Arday Journal: JAMA Date: 2000-10-04 Impact factor: 56.272
Authors: Leslie R Harrold; Jerry H Gurwitz; Janet P Tate; Richard Becker; Tammy Stuart; Anne Elwell; Martha Radford Journal: J Thromb Thrombolysis Date: 2002-08 Impact factor: 2.300
Authors: Mark H Eckman; Ruth E Wise; Katherine Naylor; Lora Arduser; Gregory Y H Lip; Brett Kissela; Matthew Flaherty; Dawn Kleindorfer; Faisal Khan; Daniel P Schauer; John Kues; Alexandru Costea Journal: Curr Med Res Opin Date: 2015-03-13 Impact factor: 2.580
Authors: Mukaila A Raji; Matthew Lowery; Yu-Li Lin; Yong-Fang Kuo; Jacques Baillargeon; James S Goodwin Journal: Ann Pharmacother Date: 2013-01-16 Impact factor: 3.154
Authors: Pablo Alonso-Coello; Victor M Montori; M Gloria Díaz; Philip J Devereaux; Gemma Mas; Ana I Diez; Ivan Solà; Mercè Roura; Juan C Souto; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ignasi Gich; Holger J Schünemann; Gordon Guyatt Journal: Health Expect Date: 2014-05-12 Impact factor: 3.377
Authors: Linda R Tulner; Jos P C M Van Campen; Ingeborg M J A Kuper; George J P T Gijsen; Cornelis H W Koks; Melvin R Mac Gillavry; Harm van Tinteren; Jos H Beijnen; Desiderius P M Brandjes Journal: Drugs Aging Date: 2010-01-01 Impact factor: 3.923
Authors: Pablo Alonso-Coello; Victor M Montori; Ivan Solà; Holger J Schünemann; Philipe Devereaux; Cathy Charles; Mercè Roura; M Gloria Díaz; Juan Carlos Souto; Rafael Alonso; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ana Isabel Diez; Ignasi Gich; Gordon Guyatt Journal: BMC Health Serv Res Date: 2008-10-27 Impact factor: 2.655